-
25 June 2026
-
25 June 2026
U.K. MHRA grants marketing authorisation for Ipsen’s Bylvay® (odevixibat) for cholestatic pruritus in Alagille syndrome, a rare liver disease
LONDON, U.K., 25 JUNE 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Bylvay® (odevixibat) a new indication for the ...
-
10 August 2026
-
10 August 2026
Cabozantinib Ipsen® (cabozantinib) accepted by Scottish Medicines Consortium for adults with advanced neuroendocrine tumours
LONDON, U.K., 10 August 2026 – Ipsen U.K. (Euronext: IPN; ADR: IPSEY) announced today that cabozantinib is accepted by the SMC for restricted use within NHS Scotland for the treatment of adult patients with unresectable or metastatic, well-differentiated...